STOCK TITAN

MEDIROM Regains Compliance with Nasdaq’s Periodic Filing Requirement

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

MEDIROM Healthcare Technologies (Nasdaq: MRM) regained compliance with Nasdaq’s periodic filing requirement, and Nasdaq closed the matter concerning its delayed annual report. The company filed its Form 20-F for the year ended December 31, 2025, on November 18, 2026, satisfying Nasdaq Listing Rule 5250(c)(1).

The separate minimum bid price deficiency remains unresolved under Nasdaq Listing Rule 5550(a)(2). MEDIROM has until April 5, 2027 to regain compliance with that requirement.

Loading...
Loading translation...
1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Minor pointNasdaq filing compliance restored after MEDIROM filed its Form 20-F; Nasdaq closed the delayed-filing matter.

Negative

  • Moderate pointMinimum bid price deficiency remains open, with an April 5, 2027 deadline to regain compliance.
Argus 15 min delay 17 alerts
+4.96% vs previous close $0.2414 last price 40.8x rel. volume Open Argus
Details

Market move: MRM +4.96% vs previous close. Nasdaq filing compliance

+21.8% Peak in 0 min
$0.21 – $0.29 Day Range
$1.91M Mkt Cap at Last Price

On Nov 20, the day this news came out, the latest delayed price for MRM is 4.96% above the previous close. Argus tracked a peak move of +21.8% during the session. Our momentum scanner has recorded 17 alerts for this stock so far that day. The latest delayed price is $0.24. Relative volume is exceptionally heavy at 40.8x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Form 20-F filing date: November 18, 2026 Minimum bid-price compliance deadline: April 5, 2027
Form 20-F filing date
November 18, 2026
For the year ended December 31, 2025; filing compliance restored
Minimum bid-price compliance deadline
April 5, 2027
Deadline to regain compliance with the separate requirement

Key Terms

form 20-f
1 terms
form 20-f regulatory
"the Company filed its Form 20-F for the year ended December 31, 2025"
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

TOKYO, Nov. 20, 2026 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq: MRM) (the “Company”) today announced that it received written notice dated November 20, 2026, from Nasdaq Listing Qualifications confirming that the Company has regained compliance with the periodic filing requirement under Nasdaq Listing Rule 5250(c)(1), because the Company filed its Form 20-F for the year ended December 31, 2025 on November 18, 2026. Accordingly, Nasdaq has closed the matter relating to the delayed filing of the Company’s annual report.

The Company remains subject to the previously disclosed minimum bid price deficiency under Nasdaq Listing Rule 5550(a)(2) and has until April 5, 2027 to regain compliance with that requirement. Nasdaq’s confirmation regarding the periodic filing requirement does not resolve this separate deficiency.

About MEDIROM Group
MEDIROM Group operates approximately 281 wellness salons under the “Re.Ra.Ku®” brand nationwide. Since 2015, we have expanded into HealthTech, offering on-demand training apps like Lav® for specific health guidance and lifestyle improvement programs. In 2020, we started manufacturing the 24/7 recharge-free smart tracker “MOTHER Bracelet®,” which is now used in REMONY, our remote monitoring system for various industries including caregiving, transportation, construction, and manufacturing.

About MEDIROM Healthcare Technologies Inc.
NASDAQ Symbol: MRM
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
Website: https://medirom.co.jp/en
Contact: ir@medirom.co.jp


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did MEDIROM (MRM) regain compliance with Nasdaq’s periodic filing requirement?

MEDIROM regained compliance by filing its Form 20-F for the year ended December 31, 2025, on November 18, 2026. Nasdaq confirmed compliance and closed the delayed-filing matter.

Did MEDIROM (MRM) also resolve its Nasdaq minimum bid price deficiency?

No. The minimum bid price deficiency remains unresolved, and MEDIROM has until April 5, 2027 to regain compliance with that separate requirement.

Keep reading